Advancing care for acute heart failure-no time to relax

The Lancet

Volumn 373, Issue 9673, 2009, Pages 1401-1402

  Hernandez, Adrian F ^a   Granger, Christopher B ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOSIMENDAN; MILRINONE; NESIRITIDE; RELAXIN;

ACUTE HEART FAILURE; ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE COST; HEALTH CARE SYSTEM; HEART LEFT VENTRICLE FUNCTION; HUMAN; MORTALITY; PATIENT CARE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 64949097265     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)60653-X     Document Type: Note

References (13)

1. Lloyd-Jones D., Adams R., Carnethon M., et al. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 119 (2009) 480-486
2. Curtis L.H., Greiner M.A., Hammill B.G., et al. Early and long-term outcomes of heart failure in elderly persons, 2001-2005. Arch Intern Med 168 (2008) 2481-2488
3. Fonarow G.C., Abraham W.T., Albert N.M., et al. Association between performance measures and clinical outcomes for patients hospitalized with heart failure. JAMA 297 (2007) 61-70
4. Cuffe M.S., Califf R.M., Adams Jr. K.F., et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 287 (2002) 1541-1617
5. Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 287 (2002) 1531-1540
6. Poole-Wilson P.A. Treatment of acute heart failure: out with the old, in with the new. JAMA 287 (2002) 1578-1580
7. Teerlink J.R., Metra M., Felker G.M., et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet (2009) 10.1016/S0140-6736(09)60622-X published online March 29, 2009.
8. Gheorghiade M., Abraham W.T., Albert N.M., et al. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 296 (2006) 2217-2226
9. McMurray J.J., Teerlink J.R., Cotter G., et al., for the VERITAS Investigators. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA 298 (2007) 2009-2019
10. Torre-Amione G., Young J.B., Colucci W.S., et al. Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 42 (2003) 140-147
11. Gheorghiade M., Gattis W.A., O'Connor C.M., et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 291 (2004) 1963-1971
12. Cohn J.N., Goldstein S.O., Greenberg B.H., et al., for The Vesnarinone Trial Investigators. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. N Engl J Med 339 (1998) 1810-1816
13. Hernandez A.F., O'Connor C.M., Starling R.C., et al. Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF). Am Heart J 157 (2009) 271-277